Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19–related Acute Respiratory Distress Syndrome: Worth the Effort?

To the Editor:

According to Chinese and Italian reports, 15–42% of patients with coronavirus disease (COVID-19) develop acute respiratory distress syndrome (ARDS), with a 60% mortality rate (1–3). Venovenous extracorporeal membrane oxygenation (VV-ECMO) is therefore considered a rescue therapy to be used in the most severe ARDS, as recommended by the World Health Organization’s interim guidelines for the management of patients with COVID-19 (4). However, without a significant impact on mortality, the benefit of ECMO in ARDS remains controversial (5). Generally, only few data on the use of ECMO in the present pandemic are available (1, 2) with a short follow-up (6, 7). However, accurately selecting patients with COVID-19–related ARDS, who may be good candidates for ECMO support, is important during a pandemic characterized by limited medical resources.

Methods

We prospectively included all patients referred to the five ICUs of the Strasbourg University Hospital, between March 3 and April 1, 2020, for severe ARDS due to COVID-19 (confirmed by RT-PCR test), and that had been supported by ECMO after failure of optimal medical treatment, including neuromuscular blocking agents, protective ventilation, and high positive end-expiratory pressure (PEEP). According to EOLIA (ECMO to Rescue Lung Injury in Severe ARDS) criteria (5), patients were eligible for ECMO if they developed a refractory ARDS defined by a PaO2/FIO2 < 80 mm Hg or a pH < 7.25 with a PaCO2 > 60 mm Hg for more than 6 hours with a FiO2 > 80%, despite low-pressure ventilation strategies and no participation of fluid overload. The contraindications for ECMO implantation were an age older than 70 years and severe comorbidities, including severe chronic respiratory failure, severe cardiac failure, and Child Pugh C cirrhosis. Invasive

References

1. MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA [online ahead of print] 19 Feb 2020; DOI: 10.1001/jama.2020.2342.

2. Ramanathan K, Antognini D, Combos A, Paden M, Zakhary B, Ogino M, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med 2020;8:518–526.

3. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323:1843–1844.

4. Fisher D, Heymann D. Q&A: the novel coronavirus outbreak causing COVID-19. BMC Med 2020;18:57.

5. Corman VM, Landt O, Kaiser M, Molkenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25:2000045.

Copyright © 2020 by the American Thoracic Society
Table 1. Clinical Presentation and Clinical Outcomes of ECMO
Patient Population (N = 17)

| Characteristics | Patients (N = 17) |
|-----------------|------------------|
| Age, yr         | 56 (30–76)       |
| Sex, M          | 16 (94.1)        |
| Obesity         | 10 (58.8)        |
| Hypertension    | 9 (52.9)         |
| Diabetes        | 3 (17.6)         |
| Antiviral treatment | 9 (52.9) |
| Lopinavir-ritonavir | 8 (47.1) |
| Hydroxychloroquine | 8 (47.1) |
| Corticosteroid  | 8 (47.1)         |
| Days of ventilation before ECMO implantation | 4 (1–17) |
| SOFA score at implantation              | 8 (3–15)      |

Respiratory parameters and adjunctive therapeutics at ECMO implantation

- Neumuscular blockade: 17 (100)
- Prone positioning session: 16 (94.1)
- Inhaled nitric oxide: 5 (29.4)
- \( FIO_2 \): 100 (50–100)
- \( PaO_2/FIO_2 \) ratio, mm Hg: 71 (52–134)
- \( SaO_2 \), %: 90 (79–99)
- \( Vt \), ml/kg of predicted body weight: 5.9 (3.5–7.1)
- Respiratory rate, breaths/min: 31 (20–35)
- PEEP, cm of water: 14 (11–16)
- Plateau pressure, cm of water: 29 (20–37)
- Driving pressure, cm of water: 15 (7–23)
- Compliance, ml/cm of water: 26 (17–55)
- Oxygenation index, cm of water/mm Hg: 29 (14–39)

Respiratory parameters under ECMO

- \( SaO_2 \), %: 97 (92–100)
- \( Vt \), ml/kg of predicted body weight: 3.9 (1.7–6.1)
- Respiratory rate, breaths/min: 20 (10–26)
- PEEP, cm of water: 12 (8–16)
- Plateau pressure, cm of water: 26 (20–39)
- Driving pressure, cm of water: 14 (8–23)
- Prone positioning session during ECMO: 0
- Anticoagulation with unfractioned heparin: 17 (100)

Respiratory parameters at ECMO weaning

- \( PaO_2/FIO_2 \) ratio, mm Hg: 177 (53–281)
- PEEP, cm of water: 10 (5–15)
- Plateau pressure, cm of water: 26 (12–31)
- Driving pressure, cm of water: 15.5 (4–24)
- Compliance, ml/cm of water: 29.5 (11–61)
- Oxygenation index, cm of water/mm Hg: 10 (5–25)

Evolution at follow-up

- Mortality at day 60: 6 (35.3)
- ICU discharge at day 60: 10 (58.8)

Adverse effect under ECMO

- Hemorrhagic shock: 1 (5.9)
- Bleeding leading to transfusion: 6 (35.3)
- Transfusion of packed red blood cells, units: 4 (0–26)

Correspondence

461

Table 1. (Continued)

| Characteristics | Patients (N = 17) |
|-----------------|------------------|
| Thrombopenia leading to transfusion | 1 (5.9) |
| Cardiac tamponade | 1 (5.9) |
| Stroke | 1 (5.9) |
| Thrombophlebitis or pulmonary embolism | 3 (17.6) |
| Oxygenator thrombosis | 2 (11.8) |
| Ventilator-associated pneumonia treated with antibiotics | 10 (58.8) |
| Renal replacement therapy | 12 (70) |
| Gas embolism | 0 |

Definition of abbreviations: ECMO = extracorporeal membrane oxygenation; PEEP = positive end-expiratory pressure; SOFA = Sequential Organ Failure Assessment.

Data are reported as either median (range) or n (%). Percentages may not total 100 because of rounding. Obesity is defined by a body mass index (weight divided by the square of the height) >30 kg/m². Organ failure was assessed with the SOFA on a scale from 0 to 24, with higher scores indicating more severe organ failure. The driving pressure is the difference between plateau pressure and PEEP. The compliance is the \( Vt \) divided by the driving pressure. The oxygenation index is mean airway pressure x \( FIO_2 \) x 100/Pao2. Hemorrhagic shock was defined as hemorrhage leading to more than five units of packed red cells during 1 day and associated with hypotension.

Mechanical ventilation for more than 7 days was a relative contraindication.

This study was approved by the institutional ethics committee of the Strasbourg University Hospital (ClinicalTrials ID: NCT04343404). Informed consent was waived as part of a public health outbreak investigation. SAS version 9.4 (SAS Institute) was used for all statistical analyses. Continuous variables are presented as median and ranges and were compared using nonparametric signed rank tests.

Results

Seventeen patients (4.5% of all those with ARDS admitted to our hospital’s ICUs during the study period, n = 377) were supported by ECMO. The clinical presentation, ICU therapies, and outcomes are shown in Table 1. At the time of ECMO implantation, median Pao2/Fio2 was 71 (52–134) mm Hg and Sequential Organ Failure Assessment score was 8 (3–15). Sixteen patients had been prone positioned before ECMO implantation.

Sixteen patients were supported with VV-ECMO (12 Avalon cannula and 4 jugulofemoral cannulations). One was supported with venoarterial femorofemoral ECMO because of respiratory failure complicated by cardiogenic shock due to pulmonary embolism. All patients were eligible for ECMO because of a PaO2/FIO2 < 80 mm Hg (n = 16) or blood pH of <7.25 with a PaCO2 of at least 60 mm Hg for more than 6 hours (n = 1). The median blood flow was 4 (0–6) L/min. In accordance with the French Society of Hematology’s recommendations for patients with COVID-19, all patients were treated with therapeutic dosing of unfractioned heparin (anti-Xa 0.5–0.7 UI/ml) (8).

After ECMO implantation, the median \( Vt \) was significantly decreased from 5.9 to 3.9 ml/kg (P < 0.01) and PEEP from 14 to 12 cm of water (P < 0.02) with a lower plateau pressure:
26 (12–31) versus 29 (20–37) cm H₂O (P < 0.05). The median duration under ECMO was 9 (0–16) days. After weaning ECMO, the median oxygenation index decreased compared with the day of ECMO implantation (10 [5–25] vs. 29 [14–39] cm H₂O/mm Hg; P = 0.01), indicating better oxygenation. Compliance also increased from 26 (17–55) to 29.5 (11–61) ml/cm H₂O (P = 0.05). Under ECMO, six patients had bleeding complications requiring transfusion. Most of the complications (in 5/6 patients, 83.3%) were due to bleeding at site of cannula insertion, and one was the result of a gastrointestinal bleeding. Despite therapeutic dosing of unfractioned heparin, we observed three oxygenator thromboses in two patients, and four patients developed thrombotic or ischemic complications under ECMO (Table 1).

At day 60, six patients (35.3%) had died and only one (5.9%) had been weaned from mechanical ventilation and discharged from the ICU. Three (17.6%) patients were still hospitalized, and seven patients were discharged from the hospital (*). ECMO = extracorporeal membrane oxygenation.

ECMO support is associated with an increased risk of both thrombotic and hemorrhagic complications. Considering the high risk of thrombotic complications in patients with severe COVID-19, we chose higher anticoagulation targets for all of our patients than usual, even if most of them were under VV-ECMO. Indeed, a high proportion of patients with COVID-19 developed life-threatening thrombotic complications. In an autopsy series (9), most of the patients were diagnosed with deep vein thrombosis or pulmonary embolisms. Furthermore, we have recently demonstrated that despite anticoagulation, patients with ARDS related to COVID-19 developed more thrombotic complications, secondary to the major systemic inflammatory response along with endothelial dysfunction (10). Furthermore, although 35.3% of the patients required blood transfusion, only one (5.8%) has developed hemorrhagic shock. Considering the high risk of thrombotic events in patients with COVID-19, we suggest that a therapeutic anticoagulation may be considered. Otherwise, despite higher targets of anticoagulation, we failed to prevent oxygenator thrombosis, requiring an urgent switch of the circuit. Indeed, only 7% of the circuits were changed in the EOLIA study because of clotting, compared with 12% in our cohort. Thus, the thrombotic complications seem to be more life-threatening than the hemorrhagic ones.

Considering the high frequency of severe adverse events, ECMO should probably remain a rescue therapy and therefore be undertaken only in ECMO-expert centers with adequate resources. In our cohort, one patient did indeed die during cannulation secondary to a cardiac tamponade.

The main strength of our study is to prospectively describe the clinical course of patients with COVID-19 who required ECMO, particularly as only few data are available. Our results are however limited by their single-center character. In conclusion, although VV-ECMO is burdened with a high rate of life-threatening complications, it might be considered as a
rescue therapy in refractory COVID-19 ARDS. In addition, an adequate higher level of therapeutic anticoagulation than usual should probably be considered.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Acknowledgment: The authors thank Pierre Diemunch, M.D., Ph.D., Olivier Collange, M.D., Ph.D., Jean Philippe Mazzucchelli, M.D., Ph.D., and Marion Villard, M.D., and acknowledge the persistent and tireless work of the extracorporeal perfusion team (Department of Thoracic and Cardiovascular Surgery).

Pierre-Emmanuel Falcoz, M.D., Ph.D.*
Alexandra Monnier, M.D.*
Strasbourg University Hospital
Strasbourg, France

Marc Puyraveau, M.D., M.Sc.
uMETR-INSERM CIC 431
Besançon, France

and

Besançon University Hospital
Besançon, France

Stephanie Perrier, M.D.
Pierre-Olivier Ludes, M.D.
Anne Olland, M.D., Ph.D.
Paul-Michel Mertes, M.D., Ph.D.
Francis Schneider, M.D., Ph.D.
Julie Helms, M.D., Ph.D.
Strasbourg University Hospital
Strasbourg, France

Ferhat Meziani, M.D., Ph.D.†
University of Strasbourg
Strasbourg, France

and

Strasbourg University Hospital
Strasbourg, France

For the CRICS TRIGGERSEP Group

*These authors contributed equally to this work.
†Corresponding author (e-mail: ferhat.meziani@chu-strasbourg.fr).

References

1. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–481.

2. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al.; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574–1581.

3. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201:1430–1434.

4. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. 2020 [accessed 2020 Apr 12]. Available from: http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.

5. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, et al.; EOLIA Trial Group, REVIVA, and ECMONet. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 2018;378:1965–1975.

6. Jacobs JP, Stammers AH, St Louis J, Hayanga JWA, Firstenberg MS, Mongero LB, et al. Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 328 patients. ASAIO J [online ahead of print] 17 Apr 2020; DOI: 10.1097/MAT.0000000000001185.

7. Sultan I, Habertheuer A, Usman AA, Kilic A, Gnaill E, Frisica ME, et al. The role of extracorporeal life support for patients with COVID-19: preliminary results from a statewide experience. J Card Surg [online ahead of print] 25 Apr 2020; DOI: 10.1111/jocs.14583.

8. Sussen S, Tacquard C, Godon A, Mansour A, Garrigue D, Nguyen P, et al. Treatment anticoagulant for la prévention du risque thrombotique chez le patient hospitalisé avec le COVID-19 et surveillance de l’hémostase, propositions du GIHP et du GHFT [accessed 2020 Apr 3]. Available from: https://site.Geh.t.org/actu/propositions-du-gftn-gihp-pour-le-traitement-anticoagulant-pour-la-prevention-du-risque-thrombotique-chez-un-patient-hospitalise-avec-COVID-19/.

9. Wichmann D, Sperhake JP, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med [online ahead of print] 6 May 2020; DOI: 10.7326/M20-2003.

10. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al.; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089–1098.

Copyright © 2020 by the American Thoracic Society

Sonographic B-Lines, Fluid Resuscitation, and Hypoxemia in Malawian Patients with Suspected Sepsis

To the Editor:

The optimal approach to fluid resuscitation for patients with sepsis is uncertain. Data from sub-Saharan Africa have indicated...